Bingham McCutchen

New York Life Appoints Sandi Tillotson to Chief Compliance Officer

Retrieved on: 
Tuesday, March 7, 2023
Professional Services, Insurance, Human Resources, Finance, Tufts University, United, Office of the General Counsel for the Department of the Treasury, Civil Service (United Kingdom), Columbia Law School, Lawsuit, Operational risk management, United Nations, General counsel, Bingham McCutchen, Senior, Associate, Management, New York Life Insurance Company

New York Life, America's largest mutual life insurer1, today announced the appointment of Senior Vice President Sandi Tillotson to Chief Compliance Officer.

Key Points: 
  • New York Life, America's largest mutual life insurer1, today announced the appointment of Senior Vice President Sandi Tillotson to Chief Compliance Officer.
  • She will report to Michael McDonnell, General Counsel at New York Life.
  • Having joined New York Life in 2003 as an Associate Counsel in the Office of the General Counsel, Ms. Tillotson has served as the Head of the Corporate Risk Practice team within Operational Risk Management, in a managerial position within the Litigation team, and as Chief of Staff to Sheila Davidson, now Executive Vice President and Chief Legal & Administrative Officer at New York Life.
  • Prior to her time with New York Life, Ms. Tillotson was a Litigation Associate at Bingham McCutchen and worked as a Public Affairs Specialist at the U.S. Mission to the United Nations.

Surface Oncology Appoints Theresa Boni as General Counsel

Retrieved on: 
Tuesday, March 15, 2022
Time, Bingham McCutchen, Boston University School of Law, Thermo Fisher Scientific, GLOBE, Novartis, Annual report, Patient, IL-27, CCR8, Private Securities Litigation Reform Act, Tumor microenvironment, Risk, COVID-19, Forward-looking statement, Security (finance), IND, CD39, Thermo Electron, GlaxoSmithKline, CD73, Cancer, Boston Scientific, Union College, U.S. Securities and Exchange Commission, PVRIG, Houghton Mifflin Harcourt, Pharmaceutical industry, Surface

CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of Theresa Boni, J.D., as general counsel and senior vice president, legal.

Key Points: 
  • CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of Theresa Boni, J.D., as general counsel and senior vice president, legal.
  • Ms. Boni has more than 20 years of legal experience spanning the biopharmaceutical and medical device industries.
  • I am thrilled to be joining Surface at such an exciting time and to be working with the talented management and legal teams, said Ms. Boni.
  • Prior to joining Surface, Ms. Boni served as vice president, assistant general counsel at Dicerna Pharmaceuticals, vice president, associate general counsel at Kiniksa Pharmaceuticals and held senior legal positions with Boston Scientific and Thermo Electron (now Thermo Fisher Scientific).

Apexigen Announces Appointment of Francis Sarena as Chief Operating Officer

Retrieved on: 
Tuesday, January 4, 2022
Artificial facet replacement, 5, Compliance, Law, Cancer, IP, Bingham McCutchen, Law school, SAN, PDL, GLOBE, Leadership, University of California, Berkeley, Laboratory, General counsel, School, University, Therapy, Patient, Nasdaq, Strategic planning, San Francisco State University, Acquisition, Time, Sale, Abbott Laboratories, Fine chemical, Management

SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the appointment of Francis Sarena as Chief Operating Officer.

Key Points: 
  • SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the appointment of Francis Sarena as Chief Operating Officer.
  • Mr. Sarena will be responsible for leading strategic operations, driving business development, overseeing finance and investor relations and optimizing organizational functions.
  • We are thrilled to welcome Francis, an accomplished industry veteran, during this important phase of Apexigens evolution, said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen.
  • Mr. Sarena spent ten years in positions of increasing responsibility at Five Prime Therapeutics, Inc. (Nasdaq: FPRX), most recently as Chief Strategy Officer.